ArticleClinical neurophysiology practice2026
Stimulated single-fiber electromyography in the diagnostic workup of diplopia and ptosis.
Article in Clinical neurophysiology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ptosis and diplopia are common neuro-ophthalmological presentations with a broad differential diagnosis. In clinical practice, stimulated single-fiber electromyography (SFEMG) is often requested when ocular myasthenia gravis (MG) remains a diagnostic consideration after initial evaluation. This study evaluated the diagnostic contribution of stimulated SFEMG in a real-world cohort of patients referred with ptosis and/or diplopia. Methods: Patients presenting with ptosis, diplopia or both were prospectively recruited and underwent comprehensive serological, radiological, and electrophysiological assessment, including SFEMG. Normative cut-offs for stimulated concentric needle SFEMG were established from 31 healthy controls and applied to the study population. Results: A total of 115 patients were included (diplopia Conclusions: Stimulated SFEMG demonstrates high specificity in patients with ptosis and diplopia and is particularly useful in diagnostically challenging cases, including seronegative MG and RNS-negative patients. Significance: SFEMG represents a valuable second-line diagnostic tool in suspected ocular MG. Its high specificity supports its use in selected patients to confirm diagnosis and reduce the risk of MG overdiagnosis and unnecessary treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.